Plain-English translation of NCT06867991 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether combining two antibody medications— and daratumumab—can help treat anti-NMDAR encephalitis, a serious brain inflammation where the immune system mistakenly attacks nerve cells. The study involves about 200 patients and compares this new combination approach to other current treatments. Researchers believe that using these two medications together may work better because they target different immune cells that contribute to the disease.
Currently, there is no FDA-approved treatment specifically designed for this type of brain inflammation, and doctors use various medications that haven't been rigorously tested in large studies. This medication combination targets both B cells (which produce harmful antibodies) and long-lived plasma cells (which continue producing those antibodies even after B cells are depleted), addressing a gap in how we treat this serious condition.
You likely qualify if…
You likely don't qualify if…
If enrolled, you will be randomly assigned to one of three treatment groups: one receiving both study medications together, one receiving the first medication alone, or one receiving standard intravenous immunoglobulin or plasma exchange therapy. If you receive the combined treatment, you would get injections and intravenous infusions on a specific schedule over approximately six months. You would have regular follow-up visits to monitor how you're responding, check for side effects, and assess improvements in your symptoms through neurological exams and blood tests.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
China